Research Highlights

A basic research breakthrough by Margarita L. Dubocovich, PhD, reporting the effects of new molecules on circadian rhythms in mice could result in treatments for people affected by jet lag, sleep disorders or even depression.

The University at Buffalo has been awarded a five-year, $21.7 million Clinical and Translational Science Award (CTSA) from the National Institutes of Health (NIH) to continue Buffalo’s rapid trajectory growing its health care and research sectors.

Timothy F. Murphy, MD, senior associate dean for clinical and translational research and SUNY Distinguished Professor of medicine, is leading a major initiative addressing health disparities among people living on Buffalo’s East Side.

The Participate in Research portal is a new online tool that lists and updates every active clinical trial throughout the University at Buffalo.

Garwood Medical Devices, LLC, has been granted “Breakthrough Device” designation from the U.S. Food and Drug Administration (FDA) for the company’s BioPrax device, a tool it is developing to help eliminate biofilm infections on prosthetic knee implants.

The University at Buffalo has officially launched the UB Biorepository, a critical new facility in the Clinical and Translational Research Center that will serve as a powerful resource in driving biomedical innovation in academia and industry regionally and throughout the state.

Pioneering research conducted and advanced by Paresh Dandona, MD, PhD, SUNY Distinguished Professor of medicine and chief of endocrinology, diabetes and metabolism, played a key role in the European Commission’s decision to approve dapagliflozin for patients with Type 1 diabetes.

Jacobs School of Medicine and Biomedical Sciences researchers have published results of the first randomized clinical trial of a treatment in the acute phase after a sport-related concussion.

Research by Yun Wu, PhD, assistant professor of biomedical engineering, has led to a cancer-spotting tool that health care providers could eventually use in areas that lack hospitals, clinics and other treatment centers.

Researchers in the Department of Physiology and Biophysics have developed a promising therapy for Duchenne muscular dystrophy (DMD) that is moving closer to use in humans.